ライフサイエンスコーパス: cost

1 g., annual membership and meeting attendance costs).

2 ater than the adjustment accounting for seed cost.

3 quality-adjusted life years (QALYs) at lower cost.

4 asymmetry to coincide with the lowest energy cost.

5 ly associated with longer length of stay and cost.

6 its high ozone demand and the resulting high cost.

7 the optimal balance between performance and cost.

8 uce such ceramic NWs have prohibitively high cost.

9 AAA patients should not be based on relative cost.

10 chromosome scale assemblies feasible and low cost.

11 ll sequencing experiment, thereby decreasing cost.

12 associations, which leads to high sequencing cost.

13 ole in modulating the impact of a resistance cost.

14 d as possible at the minimum possible energy cost.

15 ntensity ratios of isotopologues at no extra cost.

16 ospitalization and increasing the healthcare cost.

17 ormation transmission and minimize metabolic cost.

18 ated with higher rates of adverse events and costs.

19 mbined) would each comprise the plurality of costs.

20 sociation with 5-year healthcare/social-care costs.

21 rug Benefit Formulary medication consumption costs.

22 n a game of catch-up with substantial social costs.

23 implementation of 12 h shifts to reduce wage costs.

24 sensor as a smart, user-friendly, ultra-low-cost (~0.03 $ per sweat patch), portable, selective, rap

25 testinal transplantation, adding teduglutide cost ${\$}$124,353/QALY gained.

26 on (0.3-86.1/100PY, by HIV RNA), monthly ART costs ($2,290-$3,780), and HIV per-screen costs ($38).

27 bilization is safe and may reduce healthcare costs, 2) safety criteria should be provided, 3) a proto

28 nsidering healthcare costs only, the program cost $25,500/QALY gained (95% CI $12,600-$48,600).

29 tro biosensing, including brightness(2), low cost(3) and selective manipulation of their emission(4).

30 RT costs ($2,290-$3,780), and HIV per-screen costs ($38).

31 We disaggregated costs according to intervention characteristics (deliver

32 agnitude and distribution of PrEP medication costs across the health care system are unknown.

33 unded Cooperation in Science and Technology (COST) Actions that can help facilitate inter-, multi-, a

34 Low-cost air quality sensors are promising supplements to re

35 enarios for harvest and habitat conservation costing an estimated $588 M (2016 USD) led to predicted

36 equate pain treatment, adding to the initial cost and disability.

37 portant technique in bacterial genomics, but cost and labor requirements limit large-scale applicatio

38 to change HAR, likely due to infrastructure cost and limited influence on relative profitability.

39 The ease of use, low cost and quick operation of lateral flow assays (LFA) ha

40 frared sources remain attractive given their cost and retina safety.

41 In comparison to a single mouse bed, the cost and time associated with each scan were substantial

42 e variation between measurements, as well as cost and time of analysis.

43 pants sampled less when there was a monetary cost and when the gathered information was more conclusi

44 vidence gap with an economic analysis of the costs and benefits of an illustrative double-duty interv

45 ing evolution incur a variety of pleiotropic costs and benefits with different probabilities.

46 should only be based on future-and not past-costs and benefits.

47 lular manufacture, could dramatically reduce costs and broaden accessibility.

48 A Markov model was developed to compare the costs and effectiveness of cabozantinib with best suppor

49 ivery systems are one primary determinant of costs and outcomes of most interventions, as are the psy

50 bolus injections are associated with higher costs and poor compliance and can hinder the implementat

51 e the trends of LT, reasons for readmission, costs and predictors of calendar year mortality.

52 ls and often exhibits advantages in terms of costs and sustainability.

53 , the large variability in mismatches, their costs and the relationship with functional traits highli

54 Results: We estimated TB cases, deaths, and costs and the total economic burden of TB in the United

55 research in humanization contexts may reduce costs and time spent, and ensure collection of quality d

56 eater specificity regarding patient-specific cost, and challenges communicating evidence of benefit i

57 in an efficient manner with respect to time, cost, and patient resource.

58 th significant variation in local expertise, cost, and utilization.

59 n cases, $4.0-$6.5 billion in direct medical costs, and $44.8-$64.7 billion in productivity losses.

60 implified payment administration, lower drug costs, and other factors.

61 nt-derived glioblastoma cells is a reliable, cost- and time-effective way to monitor heterogenous ort

62 Significant variation in break-even costs are observed across different technologies and sce

63 rongest at more arid sites, where water unit-costs are presumably higher.

64 These goals and costs are robust, regardless of future energy policies.

65 rsible capacity, short cyclability, and high cost, are facing ever-growing requirements for further i

66 Furthermore, we incorporated experts' cost assessments into a levelized cost of driving model.

67 The cost associated with a hybrid suite remains prohibitive

68 er the past decade, incidence, severity, and costs associated with C. difficile infection (CDI) have

69 Life expectancy and long-term costs associated with device replacement, follow-up, and

70 To reduce costs associated with goosegrass control, a post-emergen

71 tages of invasion far outweigh the long-term costs associated with mitigating ecological and economic

72 enefit in a way that allows patients to make cost-benefit analyses for themselves.

73 Here, we explore a biophysical cost-benefit principle, namely that the cell should keep

74 ications for fisheries managers weighing the costs/benefits of stocking-or removing established non-n

75 dy, we characterized the health care use and cost burdens of HDV in the United States using real-worl

76 oved HF care quality and cardiovascular care costs, but these models are not focused on addressing pa

77 antifies the potential opportunities for low-cost carbon capture and storage (CCS) scenarios with pro

78 Additionally, we quantified cost changes by subtype, such as costs due to increased

79 Cost competitive conversion of biomass-derived sugars in

80 ent, and this process makes it less time and cost consuming.

81 Costs contained drugs, monitoring and adverse events mea

82 at individuals face differential benefits or costs depending on the group's order, but empirical evid

83 As technologies and expertise improve, and costs diminish, iEcology will become an increasingly imp

84 alizations and higher CMV disease-associated costs due to delayed onset post-prophylaxis disease in t

85 quantified cost changes by subtype, such as costs due to increased healthcare utilization and saving

86 Although this sunk cost effect is widely documented and can lead to devasta

87 Using biomarker twice or thrice was cost effective only if biomarker cost was <$700.

88 use of discarded wound dressings as a novel, cost effective, accessible, and non-invasive method of i

89 mated to be cost saving (net cost <0 AUD) or cost-effective (i.e., ICER < AUD 169,361/HALY) regardles

90 sal HCV rescreening among pregnant women was cost-effective (ICER $6,000/QALY) and should be recommen

91 Screening 3-monthly was cost-effective (ICER: $4,500/QALY) compared to SQ and re

92 , laparoscopic colectomy was more frequently cost-effective across a wide range of willingness-to-pay

93 arch pathology practice and could make for a cost-effective alternative to conventional stain-based p

94 A 2-dose UVV was demonstrated to be a cost-effective alternative to no vaccination.

95 novel paper-based lab-on-a-chip to deliver a cost-effective and easy to use sensing tool for customiz

96 HS-SPME-MS-enose turned out to be a fast, cost-effective and objective approach for high throughpu

97 Cost-effective bacterial RNA-seq requires efficient phys

98 ng the hardware development much simpler and cost-effective compared to conventional DoA estimators w

99 s, this probe serves as a nondestructive and cost-effective detector for the real-time monitoring of

100 st time as a privileged scaffold for further cost-effective development of valuable colistin resistan

101 The addition of 5FC to FLU is cost-effective for cryptococcal meningitis treatment in

102 Xpert+FujiLAM was considered cost-effective if its incremental cost-effectiveness rat

103 tient outcomes and cost-savings, and remains cost-effective if only a fraction of anticipated benefit

104 This methodology can be used for rapid and cost-effective measurements of emerging materials such a

105 be screened with moderate sensitivity using cost-effective MFC.

106 These findings can contribute to refining cost-effective mitigation strategies based on fostering

107 and aflibercept NVAMD monotherapies were all cost-effective over 11 years, with bevacizumab 6.21x mor

108 and inexpensive equipment, paving the way to cost-effective single-molecule DNA sequencing, capable o

109 abolites, including signaling robustness and cost-effective storage and recycling.

110 with acquired demyelinating neuropathy is a cost-effective strategy allowing for early POEMS diagnos

111 among cisgender MSWs may be an efficient and cost-effective strategy for reducing HIV incidence in th

112 This cost-effective strategy is achieved via a two-component

113 Here, a novel and cost-effective strategy is proposed to boost the energy

114 fy an environment-friendly, sustainable, and cost-effective strategy of harvesting solar energy by so

115 tu bioremediation has been investigated as a cost-effective strategy to tackle U contamination in the

116 st-effective than ranibizumab and 3.06x more cost-effective than aflibercept.

117 e over 11 years, with bevacizumab 6.21x more cost-effective than ranibizumab and 3.06x more cost-effe

118 Thus, novel, accurate and cost-effective tools for viral load monitoring become cr

119 Revascularization was not a cost-effective treatment option from a payer/healthcare

120 rsimony of overall flux to identify the most cost-effective usage of metabolism that also best reflec

121 A lack of cost-effective, reproducible models for the study of M.

122 hether MNPs give net health benefits and are cost-effective.

123 POC testing is a promising strategy to cost-effectively improve patient outcomes in moderately

124 ol actions, sectors, and locations that most cost-effectively reduce PM(2.5) mortality.

125 Routinely reporting the costs, effectiveness, and benefits of psychological inte

126 roperties, absence of treatment requirement, cost-effectiveness (c.a. 1 euro /Kg), and easiness in th

127 When performing QoL or cost-effectiveness analyses, it is important to consider

128 y collected clinical data and can be used in cost-effectiveness analyses.

129 We did a cost-effectiveness analysis using meta-analysis and indi

130 s, but evidence supporting its frequency and cost-effectiveness is limited.

131 IHD burden and health equity, as well as the cost-effectiveness of a national ban of iTFA in Australi

132 ions about the quality, appropriateness, and cost-effectiveness of care in different areas.

133 The aim of this study was to evaluate the cost-effectiveness of implementing a stepwise objective

134 This study evaluated the cost-effectiveness of implementing national bans of high

135 We aimed to estimate the cost-effectiveness of intermittent preventive treatment

136 lier initiation of treatment and the overall cost-effectiveness of screening remains uncertain.

137 The cost-effectiveness of this approach, as well as the dire

138 considered cost-effective if its incremental cost-effectiveness ratio (USD/year-of-life saved) was <$

139 nefit of AUD$1.02 million and an incremental cost-effectiveness ratio of $4684 per QALY gained.

140 We calculated incremental cost-effectiveness ratios (ICERs) and report the mean an

141 e base case analysis, national bans produced cost-effectiveness ratios of $94 per HLYG (95% UI 73-123

142 ning low-income to high-income settings, and cost-effectiveness ratios were analysed at the country-s

143 d 90% model variability of 250 runs, using a cost-effectiveness threshold of US$500 per disability-ad

144 characteristics but also brings flexibility, cost-effectiveness, swiftness and user-friendliness.

145 Here, we present the cost-effectiveness.

146 evels of patient co-morbidity), and analysed cost-effectiveness.

147 These results show that sunk cost effects can arise in the absence of human-unique fa

148 BPSs are a labor and cost-efficient technology but are still mainly operated

149 blic health efforts; it is fast, robust, and cost-efficient, and generates full genomic sequences of

150 Exploring efficient and low-cost electrocatalysts for hydrogen evolution reaction (H

151 emometric techniques, hence, providing a low-cost, fast and accurate diagnostic approach.

152 ive patient risk have been shown to increase costs following surgery.

153 y from wildfire, but at an increasing carbon cost for forest management.

154 ysts account for ~50% of the projected total cost for large-scale production.

155 Lastly, we consider the thermodynamic cost for specificity in cellular signaling and adaptatio

156 e changes in growth are driven by the energy cost for the top material to sustain the polarization im

157 fects have not been translated into economic costs for individuals and economies in the form of lost

158 ility of the manufacturing processes and low cost have drawn ever increasing attention to fibre-based

159 e simplicity of these IDAs, coupled with low cost, high sensitivity, and ability to carry out high-th

160 RNA in situ and sequencing (PETRI-seq)-a low-cost, high-throughput prokaryotic scRNA-seq pipeline tha

161 ed weak evidence that propensity to discount cost imposed on drug seeking is associated with dependen

162 d that screening has substantial opportunity costs in low- and middle-income countries that offset it

163 t factors associated with increased eye drop cost included older age, female gender, and race or ethn

164 Accounting for all costs included in the analysis, for every 100 admissions

165 The emerging literature on cost-inclusive research in psychology suggests that deli

166 The extent of cost increase due to specific complications has not been

167 of perovskite solar cells (PSCs) using a low-cost industrial organic pigment quinacridone (QA) is pre

168 ion ability, benefit-generation willingness, cost-infliction ability, and cost-infliction willingness

169 on willingness, cost-infliction ability, and cost-infliction willingness.

170 Cost inputs (2017 Canadian dollars [C$]) were derived us

171 quick (analysis time <=15 min), requires low-cost instrumentation and sensor chips, and is also poten

172 on the part of patients to incorporation of cost into decision-making and the decision aid, requests

173 print, they are time-consuming, and the high costs involved in attending can exclude many potential p

174 ng flexibility, speed and uniformity at less cost, leading to high throughput and practical preclinic

175 associated with lower rates of bleeding, but costs limit use for some patients.

176 vention was estimated to be cost saving (net cost <0 AUD) or cost-effective (i.e., ICER < AUD 169,361

177 of systematic differences in access to care, cost may not be an appropriate surrogate for predicting

178 These costs may remain hidden during the reproductive period o

179 cerns that dialysis facilities facing higher costs might close, disrupting care delivery and access t

180 Here, we improve DropSynth, a low-cost, multiplexed method that builds gene libraries by c

181 atments, including short reaction times, low cost, no requirement for specialized equipment, and high

182 d liquid handler that can be fabricated at a cost of $1,500 using off-the-shelf and 3D-printable part

183 Finally, the cost of body inversion (upside-down rotation) on body re

184 success rates, preclinical expenditures, and cost of capital.

185 The primary outcome was average net cost of care to the healthcare system per patient, calcu

186 d experts' cost assessments into a levelized cost of driving model.

187 and processes of care; the number, type, and cost of each wish; and semistructured interviews and foc

188 This adaptation comes at the cost of enhancing mortality to a subsequent inflammatory

189 y barrier in a magnitude close to the energy cost of forming a knot randomly in the denatured state.

190 nual profit: gross profit (revenue minus the cost of goods sold); earnings before interest, taxes, de

191 ion of FadR, cell size increases, but at the cost of growth rate and accumulation of intracellular me

192 We collected patient and caregiver cost of illness information for 395 patients, with a med

193 information for 395 patients, with a median cost of illness per case of $59.99 (IQR, $24.04-$151.23)

194 ic terminal ileal perforation, with a median cost of illness per case of US $196.37 (IQR, US $72.89-4

195 mprove circuit performance, although, at the cost of increased complexity.

196 dramatic improvement in cancer has come at a cost of increased risks of life-threatening infectious c

197 The total cost of inpatient hospital admission including an explic

198 py C export (NCE, photosynthesis minus the C cost of leaf growth and maintenance) as a fitness proxy.

199 DNA libraries, thereby raising the discovery cost of novel vectors.

200 Total acquisition cost of OVP was $1302, $26.04 per patient.

201 s, and this realization could decrease total cost of ownership while increasing energy efficiency.

202 for several reagents and steps and the high cost of PCR hinder its worldwide implementation to conta

203 arcoding efficiency significantly reduce the cost of reagents and sequencing.

204 metabolic stability but occasionally at the cost of reduced permeability.

205 n exposure to predators, immune capacity and cost of reproduction.

206 Estimations of the relative cost of stance and swing matched well with previous simu

207 n be reproduced by considering the energetic cost of surviving in harsh environments and HMP patterns

208 proaches without incurring the computational cost of traditional alignment.

209 and negatively associated with any financial cost of travel to a clinic (aOR 0.86 [0.83-0.88], p<0.00

210 combined consumption of 1 107 450 kWh (at a cost of U.S. $199 341).

211 a representative, real-world population at a cost of under $100 per patient, which makes this combina

212 bon dioxide (CO(2)) per year with extraction costs of approximately US$80-180 per tonne of CO(2).

213 This study demonstrates how the costs of barrier crossings in prevailing winds can disru

214 Monetizing the results based on social costs of carbon and other air pollutant emissions highli

215 rt for our hypothesis that the physiological costs of childbearing influence later life frailty.

216 Because of the costs of clinical and experimental studies to treat and

217 use rules, in part, because they reduce the costs of decision-making through a distributed represent

218 further research into the effectiveness and costs of different regimens of IPTp-DP in settings with

219 After accounting for the costs of failed trials, the median capitalized research

220 transients more often correspond to survival costs of first reproduction rather than to permanent dis

221 Total costs of implementing strategies across the cities at pr

222 re critical for stabilizing our climate, but costs of mitigation over space, time, and stakeholder gr

223 a given environment is that where the summed costs of photosynthetic water and nutrient acquisition/u

224 ort are needed to mitigate the psychological costs of providing care during the COVID-19 pandemic.

225 educe the time complexity and physical layer costs of quantum computers.

226 interpretation of transience as a measure of costs of reproduction, since initial detections are ofte

227 vancements combined with the rapidly falling costs of sequencing now allows comparisons between multi

228 ditions in interaction with the sex-specific costs of sexual selection.

229 ologist workflows, appropriate reimbursement/cost-offsetting models, and ultimately, the active parti

230 od (TEEBAgriFood) to assess key benefits and costs on the production side of genetically modified (GM

231 When considering healthcare costs only, the program cost $25,500/QALY gained (95% CI

232 metabolism are limited by low sensitivities, costs or the use of specialized hardware.

233 lthcare provider, the average direct medical cost per case was US $58.64 (range: US $37.25 at Hospita

234 The mean costs per patient were US $847 (95% confidence interval

235 rkov models to evaluate outcomes short term (cost-per-accurate diagnosis) and long term (quality-adju

236 omponents and was aggregated to estimate the cost-per-patient based on each trial.

237 For culture-negative samples, mean cost-per-positive 16S PCR result was pound 568.37 and po

238 From an ophthalmic (medical) cost perspective, bevacizumab, ranibizumab, and afliberc

239 ent and actuation hardware into a single low-cost platform, Chi.Bio facilitates novel experimental me

240 It is thus a rapid, low cost portable test suitable for point-of-need detection

241 ustry such as drug coatings due to their low cost, processability and ease of functionalisation.

242 uperior chemical and physical stability, low-cost production, high selectivity and rapid response, MI

243 Healthcare cost reduction policies should consider the largest area

244 e we directly set national PM(2.5) mortality cost reduction targets within a global human-earth syste

245 Cost reductions can be achieved by pooling (or combining

246 ario parameters showed an outsized impact on costs relative to technology parameters.

247 However, observed costs remained more widely distributed than predictions

248 can estimate quality-adjusted life years and costs resulting from improvements in a quality metric.

249 The intervention was estimated to be cost saving (net cost <0 AUD) or cost-effective (i.e., I

250 fficient strategy which can lead to time and cost saving post-translational, covalent conjugation of

251 consumer response alone was estimated to be cost-saving by 2023, with net lifetime savings of $10.42

252 over a 10-year period and is expected to be cost-saving compared with current control efforts.

253 eat benefit in clinical practice and a large cost-saving in clinical trial recruitment.

254 Considerable energy- and cost-saving potential is present during nonproductive id

255 The clinic efficiency and cost savings achieved by eliminating formal visual acuit

256 onstrate the feasibility, acceptability, and cost savings of a stewardship program where resources ar

257 ith Atlanta, Baltimore, and Miami projecting cost savings over the 20 year study period.

258 ults in decreased mortality and a net annual cost savings to the insurer compared with usual care pro

259 d employees (fewer handovers, less overtime, cost savings).

260 l will result in better patient outcomes and cost-savings, and remains cost-effective if only a fract

261 We specifically focus on water-related low-cost sensor networks, and conceptualize them as socio-te

262 Low-income patients eligible for cost-sharing and premium subsidies in the Marketplaces [

263 s, with integrated device mass manufacturing cost still not at a competitive level for several key cl

264 quality of life, dementia and hospital care costs stratified by haematoma location.

265 ffer unparalleled advantages in terms of low cost, superior activity, and high stability.

266 hemical detection, high sensitivity, and low-cost) technologies.

267 stay (11 vs 6 d; p = 0.02), and higher total costs than patients with direct oral anticoagulant-assoc

268 level of fees or, alternatively, the maximal cost the Lightning ecosystem may impose for a given aver

269 When taking into account the cost, the FDM prostate models are the most preferred 3D

270 However, due primarily to cost, the total number of such assays that can be perfor

271 Photosynthetic 'least-cost' theory posits that the optimal trait combination f

272 avior, they've been shown to have self-image costs: Those who receive incentives view their actions l

273 The low-cost 'THz Torch' technology, which exploits the thermal

274 entific and therapeutic challenge with great cost to individuals and society.

275 between reimbursement payments and the total cost to provide care to the patient.

276 The cost to the Centers for Medicare and Medicaid Services f

277 them to subvert phage infection, but with a cost to their fitness.

278 potential risks, and quantifying associated costs to healthcare using multiscale models.

279 Finally, the costs to remove wild pigs averaged $50 per wild pig (6.8

280 to minimize environmental and health related costs to society and economy.

281 health and quality of life, with associated costs to society(3).

282 High costs to the health care system may hinder PrEP expansio

283 ng, filtration, or centrifugation, which add costs to the overall process and may reduce product yiel

284 Taken together, our work highlights how low-cost tools can automatically quantify behavior in natura

285 n-one paper chip can provide a portable, low-cost, user-friendly, sensitive, and specific NAT platfor

286 ted against different targets, and decreased cost using an industrialized process.

287 nd general functioning) and health economics/cost-utility (eg, healthcare resource use and quality-ad

288 tion model was used to calculate comparative cost-utility of intravitreal bevacizumab (IVB), intravit

289 Equivalent annual cost varied between US$1.2 (95% CI $1.1-$1.4) and US$1.5

290 thrice was cost effective only if biomarker cost was <$700.

291 Costs were driven primarily by more hospitalizations and

292 eaching and nonteaching environments, though costs were higher at teaching hospitals.

293 Aggregate costs were higher for TAVR than SAVR and were significan

294 ched $559 million per year in 2024; however, costs were offset by long-term reductions in new infecti

295 gotrophy favors lower information-processing costs whereas copiotrophy favors higher processing rates

296 The resulting estimates predict conservation cost with up to 8.5 times greater accuracy than earlier

297 Lowering external costs with fleet electrification, however, was found to

298 mong patients with the highest out-of-pocket costs, without detectable increases in health-plan spend

299 a large portion of healthcare and disability costs worldwide.

300 Specifically, teduglutide cost would need to be reduced by >65% for it to reach th